PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33010451-0 2021 CD38 downregulation modulates NAD+ and NADP(H) levels in thermogenic adipose tissues. NAD 30-34 CD38 antigen Mus musculus 0-4 33893948-3 2021 Photoactivation of astrocytes led to activation of neurogenesis and changes in the expression of molecules (Cx43 and CD38) that determine bioavailability of NAD+ to ensure proliferative activity of cells in the neurogenic niche. NAD 157-161 CD38 antigen Mus musculus 117-121 33871064-0 2021 Inhibition of CD38 and supplementation of nicotinamide riboside ameliorate lipopolysaccharide-induced microglial and astrocytic neuroinflammation by increasing NAD. NAD 160-163 CD38 antigen Mus musculus 14-18 33871064-4 2021 Our previous study demonstrated that deletion of CD38, which consumes NAD+ , suppressed cuprizone-induced demyelination, neuroinflammation and glial activation. NAD 70-74 CD38 antigen Mus musculus 49-53 33871064-5 2021 However, it is still unknown whether CD38 directly affects neuroinflammation through regulating brain NAD+ level. NAD 102-106 CD38 antigen Mus musculus 37-41 33871064-12 2021 These results suggest that CD38-mediated neuroinflammation is linked to NAD+ consumption and that boosting NAD+ by CD38 inhibition and NR supplementation directly suppress neuroinflammation in the brain. NAD 72-76 CD38 antigen Mus musculus 27-31 33871064-12 2021 These results suggest that CD38-mediated neuroinflammation is linked to NAD+ consumption and that boosting NAD+ by CD38 inhibition and NR supplementation directly suppress neuroinflammation in the brain. NAD 107-111 CD38 antigen Mus musculus 115-119 33010451-2 2021 CD38 is a NAD+-dependent enzyme involved in the regulation of different cell functions. NAD 10-13 CD38 antigen Mus musculus 0-4 33010451-4 2021 In this study we aim to understand the functional relevance of CD38 for NAD+ and energy metabolism in BAT and WAT, also using a CD38-/- mouse model. NAD 72-76 CD38 antigen Mus musculus 63-67 33010451-8 2021 Increased NAD+ levels were observed in BAT/WAT from CD38-/- compared with wild type mice, in line with CD38 being a major NAD+-consumer in AT. NAD 10-14 CD38 antigen Mus musculus 52-56 33010451-8 2021 Increased NAD+ levels were observed in BAT/WAT from CD38-/- compared with wild type mice, in line with CD38 being a major NAD+-consumer in AT. NAD 10-14 CD38 antigen Mus musculus 103-107 33010451-8 2021 Increased NAD+ levels were observed in BAT/WAT from CD38-/- compared with wild type mice, in line with CD38 being a major NAD+-consumer in AT. NAD 122-126 CD38 antigen Mus musculus 103-107 33082370-3 2020 CD38 is an enzyme that catalyses the hydrolysis of nicotinamide adenine dinucleotide (NAD+) and is a candidate molecule for regulating neurodegeneration and neuroinflammation. NAD 51-84 CD38 antigen Mus musculus 0-4 33326496-1 2020 The ability of CD38 and CD157 to utilize nicotinamide adenine dinucleotide (NAD) has received much attention because the aging-induced elevation of CD38 expression plays a role in the senescence-related decline in NAD levels. NAD 41-74 CD38 antigen Mus musculus 15-19 33326496-1 2020 The ability of CD38 and CD157 to utilize nicotinamide adenine dinucleotide (NAD) has received much attention because the aging-induced elevation of CD38 expression plays a role in the senescence-related decline in NAD levels. NAD 41-74 CD38 antigen Mus musculus 148-152 33326496-1 2020 The ability of CD38 and CD157 to utilize nicotinamide adenine dinucleotide (NAD) has received much attention because the aging-induced elevation of CD38 expression plays a role in the senescence-related decline in NAD levels. NAD 76-79 CD38 antigen Mus musculus 15-19 33326496-1 2020 The ability of CD38 and CD157 to utilize nicotinamide adenine dinucleotide (NAD) has received much attention because the aging-induced elevation of CD38 expression plays a role in the senescence-related decline in NAD levels. NAD 76-79 CD38 antigen Mus musculus 148-152 33326496-1 2020 The ability of CD38 and CD157 to utilize nicotinamide adenine dinucleotide (NAD) has received much attention because the aging-induced elevation of CD38 expression plays a role in the senescence-related decline in NAD levels. NAD 214-217 CD38 antigen Mus musculus 15-19 33326496-1 2020 The ability of CD38 and CD157 to utilize nicotinamide adenine dinucleotide (NAD) has received much attention because the aging-induced elevation of CD38 expression plays a role in the senescence-related decline in NAD levels. NAD 214-217 CD38 antigen Mus musculus 148-152 33326496-9 2020 We discuss the distinct differences in aging effects from the perspective of inhibition of NAD metabolism in CD157 and CD38 KO mice, which may contribute to differential behavioral changes during aging. NAD 91-94 CD38 antigen Mus musculus 119-123 33385109-4 2021 Boosting NAD+ via genetic or pharmacological CD38 targeting or NAD+ precursor supplementation protected mice from skin, lung, and peritoneal fibrosis. NAD 9-13 CD38 antigen Mus musculus 45-49 33385109-5 2021 In mechanistic experiments, CD38 was found to reduce NAD+ levels and sirtuin activity to augment cellular fibrotic responses, while inhibiting CD38 had the opposite effect. NAD 53-57 CD38 antigen Mus musculus 28-32 33385109-6 2021 Thus, we identify CD38 upregulation and resulting disrupted NAD+ homeostasis as a fundamental mechanism driving fibrosis in SSc, suggesting that CD38 might represent a novel therapeutic target. NAD 60-64 CD38 antigen Mus musculus 18-22 33385109-6 2021 Thus, we identify CD38 upregulation and resulting disrupted NAD+ homeostasis as a fundamental mechanism driving fibrosis in SSc, suggesting that CD38 might represent a novel therapeutic target. NAD 60-64 CD38 antigen Mus musculus 145-149 33020065-0 2020 Cell type-specific roles of CD38 in the interactions of isoniazid with NAD+ in the liver. NAD 71-75 CD38 antigen Mus musculus 28-32 33020065-3 2020 Our previous work revealed the CD38-dependent interactions of isoniazid (INH), an anti-tuberculosis drug, with NAD+ to form INH-NAD adduct. NAD 111-115 CD38 antigen Mus musculus 31-35 33020065-3 2020 Our previous work revealed the CD38-dependent interactions of isoniazid (INH), an anti-tuberculosis drug, with NAD+ to form INH-NAD adduct. NAD 111-114 CD38 antigen Mus musculus 31-35 33020065-8 2020 These data suggest that hepatic non-parenchymal cells, such as KC and HSC, are the major cell types responsible for the CD38-dependent interactions of INH with NAD+ in the liver. NAD 160-164 CD38 antigen Mus musculus 120-124 33020065-10 2020 Our work also revealed the essential roles of non-parenchymal cells including KC and HSC in the CD38-dependent interactions of NAD+ with INH, leading to the formation of both INH-NAD and AcINH-NAD in the liver. NAD 127-131 CD38 antigen Mus musculus 96-100 33120985-9 2020 Thus, NAD+ is a significant source of adenosine and UA in the airways in mouse models of allergic airway disease, and the capacity for their generation from NAD+ is augmented by CD38, a major NADase with high affinity for NAD+. NAD 6-10 CD38 antigen Mus musculus 178-182 33120985-9 2020 Thus, NAD+ is a significant source of adenosine and UA in the airways in mouse models of allergic airway disease, and the capacity for their generation from NAD+ is augmented by CD38, a major NADase with high affinity for NAD+. NAD 157-161 CD38 antigen Mus musculus 178-182 33120985-9 2020 Thus, NAD+ is a significant source of adenosine and UA in the airways in mouse models of allergic airway disease, and the capacity for their generation from NAD+ is augmented by CD38, a major NADase with high affinity for NAD+. NAD 157-161 CD38 antigen Mus musculus 178-182 33082370-3 2020 CD38 is an enzyme that catalyses the hydrolysis of nicotinamide adenine dinucleotide (NAD+) and is a candidate molecule for regulating neurodegeneration and neuroinflammation. NAD 86-90 CD38 antigen Mus musculus 0-4 32572044-6 2020 NAD is the substrate for the CD157- and CD38-dependent production of cADPR. NAD 0-3 CD38 antigen Mus musculus 40-44 32363189-3 2020 Mechanistic studies demonstrated that overexpression of CD38 specifically downregulated the expression of Rab7 and its adaptor protein pleckstrin homology domain-containing protein family member 1 (PLEKHM1) through nicotinamide adenine dinucleotide (NAD)-dependent and non-NAD-dependent pathways, respectively. NAD 215-248 CD38 antigen Mus musculus 56-60 32300965-3 2020 However, age-related DNA damage and increased SASP activate PARP-1 and CD38, the enzymes competing with SIRTs for NAD+. NAD 114-118 CD38 antigen Mus musculus 71-75 32363189-3 2020 Mechanistic studies demonstrated that overexpression of CD38 specifically downregulated the expression of Rab7 and its adaptor protein pleckstrin homology domain-containing protein family member 1 (PLEKHM1) through nicotinamide adenine dinucleotide (NAD)-dependent and non-NAD-dependent pathways, respectively. NAD 273-276 CD38 antigen Mus musculus 56-60 32363189-3 2020 Mechanistic studies demonstrated that overexpression of CD38 specifically downregulated the expression of Rab7 and its adaptor protein pleckstrin homology domain-containing protein family member 1 (PLEKHM1) through nicotinamide adenine dinucleotide (NAD)-dependent and non-NAD-dependent pathways, respectively. NAD 250-253 CD38 antigen Mus musculus 56-60 27939939-1 2017 CD38 is an ectoenzyme that catalyzes the conversion of beta-nicotinamide adenine dinucleotide (beta-NAD) to cyclic adenosine diphosphoribose (cADPR) and adenosine diphosphoribose (ADPR) and NADP to nicotinic acid adenine dinucleotide phosphate (NAADP) and adenosine diphosphoribose-2"-phosphate (ADPR-P). NAD 55-93 CD38 antigen Mus musculus 0-4 29719225-0 2018 A Potent and Specific CD38 Inhibitor Ameliorates Age-Related Metabolic Dysfunction by Reversing Tissue NAD+ Decline. NAD 103-107 CD38 antigen Mus musculus 22-26 29719225-3 2018 We recently demonstrated that the NADase CD38 has a central role in age-related NAD+ decline. NAD 80-84 CD38 antigen Mus musculus 41-45 29719225-4 2018 Here we show that a highly potent and specific thiazoloquin(az)olin(on)e CD38 inhibitor, 78c, reverses age-related NAD+ decline and improves several physiological and metabolic parameters of aging, including glucose tolerance, muscle function, exercise capacity, and cardiac function in mouse models of natural and accelerated aging. NAD 115-119 CD38 antigen Mus musculus 73-77 30114710-6 2018 RESULTS: Our results revealed that CD38 deficiency significantly elevated the intracellular glutathione (GSH) concentration and GSH/GSSG ratio, decreased the contents of free fatty acids and increased intracellular NAD+ level in heart from CD38-/- mice fed with HFD. NAD 215-219 CD38 antigen Mus musculus 35-39 31244614-1 2019 CD38 is an enzyme that catalyzes the synthesis of cyclic adenosine diphosphate-ribose from nicotinamide adenine dinucleotide (NAD+). NAD 91-124 CD38 antigen Mus musculus 0-4 31244614-1 2019 CD38 is an enzyme that catalyzes the synthesis of cyclic adenosine diphosphate-ribose from nicotinamide adenine dinucleotide (NAD+). NAD 126-130 CD38 antigen Mus musculus 0-4 31244614-7 2019 Further experiments revealed that these observations were associated with reduced levels of glial activation and inflammatory responses including phagocytosis, most likely through the enhanced level of NAD+ in CD38-deleted condition. NAD 202-206 CD38 antigen Mus musculus 210-214 29977153-8 2018 However, re-expression of CD38 in the knockdown clones reversed the effect on Sirt1/NF-kappaB/TLR2 signaling, which is NAD-dependent. NAD 119-122 CD38 antigen Mus musculus 26-30 28807785-6 2017 CD38 knockdown or 8-Br-cADPR treatment significantly reduced NAD+, cADPR and intracellular Ca2+ levels. NAD 61-65 CD38 antigen Mus musculus 0-4 27939939-1 2017 CD38 is an ectoenzyme that catalyzes the conversion of beta-nicotinamide adenine dinucleotide (beta-NAD) to cyclic adenosine diphosphoribose (cADPR) and adenosine diphosphoribose (ADPR) and NADP to nicotinic acid adenine dinucleotide phosphate (NAADP) and adenosine diphosphoribose-2"-phosphate (ADPR-P). NAD 95-103 CD38 antigen Mus musculus 0-4 27592202-6 2016 Regulation of the SIRT/NAD system was associated with early (SIRT4, SIRT7, NAPRT1 and NMNAT2) and late phases (NMNAT3, NMRK2, ABCA1 and CD38) of glucose intolerance. NAD 23-26 CD38 antigen Mus musculus 136-140 27518087-2 2017 NAD+ depletion following ischemic insult can result in cell death and has been associated with over-activation of poly-ADP-ribose polymerase PARP1 as well as an increase in NAD+ consuming enzyme CD38. NAD 0-4 CD38 antigen Mus musculus 195-199 27518087-2 2017 NAD+ depletion following ischemic insult can result in cell death and has been associated with over-activation of poly-ADP-ribose polymerase PARP1 as well as an increase in NAD+ consuming enzyme CD38. NAD 173-177 CD38 antigen Mus musculus 195-199 27518087-6 2017 Decrease of hippocampal NAD+ levels detected during reperfusion in WT mice was only transient in CD38KO animals, suggesting that CD38 contributes to post-ischemic NAD+ catabolism. NAD 24-28 CD38 antigen Mus musculus 129-133 27518087-6 2017 Decrease of hippocampal NAD+ levels detected during reperfusion in WT mice was only transient in CD38KO animals, suggesting that CD38 contributes to post-ischemic NAD+ catabolism. NAD 163-167 CD38 antigen Mus musculus 129-133 27518087-9 2017 Thus, the absence of CD38 activity can not only directly affect inflammatory response, but also result in unpredicted alterations in the expression levels of enzymes participating in NAD+ metabolism. NAD 183-187 CD38 antigen Mus musculus 21-25 27547294-4 2016 Here, we showed that the hearts of CD38 deficient mice or wild type mice supplied with exogenous NAD were significantly protected from ischemia/reperfusion injury, seen as reduction of the myocardial infarct sizes when the mice were subjected to 30 min ischemia followed by 24 hours of reperfusion. NAD 97-100 CD38 antigen Mus musculus 35-39 26089537-4 2015 The contribution of the ADO-generating ectoenzymes in the regulatory response was shown by: 1) selective inhibition of the enzymatic activities of CD39, CD73, and CD38; 2) the ability of suppressor T cells to convert exogenously added ATP and NAD(+) to ADO; and 3) a positive correlation between ectoenzyme expression, ADO levels, and suppression abilities. NAD 243-249 CD38 antigen Mus musculus 163-167 25893674-2 2015 The nicotinamide adenine dinucleotide (NAD) glycohydrolase CD38, which is expressed by neurons, astrocytes, and microglial cells, regulates inflammatory and repair processes in the brain and other tissues by degrading NAD and repressing the activity of other NAD-consuming enzymes and by producing NAD-derived metabolites that regulate calcium signaling and migration of inflammatory cells. NAD 4-37 CD38 antigen Mus musculus 59-63 26267483-3 2015 Two of these CD38 inhibitors, 1ah and 1ai, were shown to elevate NAD tissue levels in liver and muscle in a diet-induced obese (DIO) C57BL/6 mouse model. NAD 65-68 CD38 antigen Mus musculus 13-17 26287487-6 2015 CD38, a multi-functional membrane receptor and enzyme, consumes NAD+ to generate products such as cyclic-ADP-ribose. NAD 64-68 CD38 antigen Mus musculus 0-4 26287487-7 2015 CD38 knockout mice show elevated tissue and blood NAD+ level. NAD 50-54 CD38 antigen Mus musculus 0-4 26287487-10 2015 These animal model results suggest that elevation of tissue NAD+ through genetic ablation of CD38 can profoundly alter energy homeostasis in animals that are maintained on a calorically-excessive Western diet. NAD 60-64 CD38 antigen Mus musculus 93-97 25893674-2 2015 The nicotinamide adenine dinucleotide (NAD) glycohydrolase CD38, which is expressed by neurons, astrocytes, and microglial cells, regulates inflammatory and repair processes in the brain and other tissues by degrading NAD and repressing the activity of other NAD-consuming enzymes and by producing NAD-derived metabolites that regulate calcium signaling and migration of inflammatory cells. NAD 39-42 CD38 antigen Mus musculus 59-63 25893674-2 2015 The nicotinamide adenine dinucleotide (NAD) glycohydrolase CD38, which is expressed by neurons, astrocytes, and microglial cells, regulates inflammatory and repair processes in the brain and other tissues by degrading NAD and repressing the activity of other NAD-consuming enzymes and by producing NAD-derived metabolites that regulate calcium signaling and migration of inflammatory cells. NAD 218-221 CD38 antigen Mus musculus 59-63 25893674-2 2015 The nicotinamide adenine dinucleotide (NAD) glycohydrolase CD38, which is expressed by neurons, astrocytes, and microglial cells, regulates inflammatory and repair processes in the brain and other tissues by degrading NAD and repressing the activity of other NAD-consuming enzymes and by producing NAD-derived metabolites that regulate calcium signaling and migration of inflammatory cells. NAD 218-221 CD38 antigen Mus musculus 59-63 25893674-2 2015 The nicotinamide adenine dinucleotide (NAD) glycohydrolase CD38, which is expressed by neurons, astrocytes, and microglial cells, regulates inflammatory and repair processes in the brain and other tissues by degrading NAD and repressing the activity of other NAD-consuming enzymes and by producing NAD-derived metabolites that regulate calcium signaling and migration of inflammatory cells. NAD 218-221 CD38 antigen Mus musculus 59-63 25828863-5 2015 The inhibitors should allow for a more detailed assessment of how NAD elevation via CD38 inhibition affects physiology in NAD deficient states. NAD 66-69 CD38 antigen Mus musculus 84-88 25828863-5 2015 The inhibitors should allow for a more detailed assessment of how NAD elevation via CD38 inhibition affects physiology in NAD deficient states. NAD 122-125 CD38 antigen Mus musculus 84-88 22293203-1 2012 CD38 is a multifunctional enzyme that can not only generate cyclic adenosine diphosphate-ribose (cADPR) - a key Ca(2+) -mobilizing second messenger - by consuming NAD(+), but also hydrolyze extracellular NAD(+). NAD 163-169 CD38 antigen Mus musculus 0-4 23172919-0 2013 Flavonoid apigenin is an inhibitor of the NAD+ ase CD38: implications for cellular NAD+ metabolism, protein acetylation, and treatment of metabolic syndrome. NAD 42-46 CD38 antigen Mus musculus 51-55 23172919-6 2013 Moreover, CD38 knockout mice have higher NAD(+) levels and are protected against obesity and metabolic syndrome. NAD 41-47 CD38 antigen Mus musculus 10-14 23172919-7 2013 Here, we show that CD38 regulates global protein acetylation through changes in NAD(+) levels and sirtuin activity. NAD 80-86 CD38 antigen Mus musculus 19-23 23172919-9 2013 We show that pharmacological inhibition of CD38 results in higher intracellular NAD(+) levels and that treatment of cell cultures with apigenin decreases global acetylation as well as the acetylation of p53 and RelA-p65. NAD 80-86 CD38 antigen Mus musculus 43-47 23172919-11 2013 Our results show that CD38 is a novel pharmacological target to treat metabolic diseases via NAD(+)-dependent pathways. NAD 93-99 CD38 antigen Mus musculus 22-26 22700727-4 2012 CD38 is a multifunctional ectoenzyme that uses nicotinamide adenine dinucleotide as a substrate to generate second messengers. NAD 47-80 CD38 antigen Mus musculus 0-4 22351627-7 2012 Degradation of beta-NAD(+) to ADPR and other metabolites appears to be mediated by pathways besides CD38, the main NAD-glycohydrolase in mammals. NAD 15-26 CD38 antigen Mus musculus 100-104 24578339-2 2014 CD38 is an ectoenzyme that consumes NAD(+) to produce cyclic ADP-ribose (cADPR), a potent agonist of ryanodine receptors. NAD 36-42 CD38 antigen Mus musculus 0-4 23123323-13 2013 CD38 was found to transduce the extracellular NAD(+) signal. NAD 46-52 CD38 antigen Mus musculus 0-4 22293203-1 2012 CD38 is a multifunctional enzyme that can not only generate cyclic adenosine diphosphate-ribose (cADPR) - a key Ca(2+) -mobilizing second messenger - by consuming NAD(+), but also hydrolyze extracellular NAD(+). NAD 204-210 CD38 antigen Mus musculus 0-4 21586363-4 2011 The CD38/CD157 family of extracellular NADases degrades NAD(+) and generates Ca(2+)-active metabolites, including cyclic ADP ribose and ADP ribose. NAD 56-62 CD38 antigen Mus musculus 4-8 22100343-3 2012 Recently, CD38-associated ADP-ribosylcyclase has been reported to use an NAD(P)H oxidase product, NAD(+) or NADP(+), to produce cyclic ADP-ribose (cADPR) or nicotinic acid adenine dinucleotide phosphate, which mediates intracellular Ca(2+) signaling. NAD 98-104 CD38 antigen Mus musculus 10-14 23213344-2 2012 The enzymatic activity of CD38 generates cyclic ADP-ribose from beta-NAD. NAD 64-72 CD38 antigen Mus musculus 26-30 22033928-1 2011 The ADP-ribosyl cyclase CD38 whose catalytic domain resides in outside of the cell surface produces the second messenger cyclic ADP-ribose (cADPR) from NAD(+). NAD 152-158 CD38 antigen Mus musculus 24-28 22033928-3 2011 It has been known that intracellular NAD(+) approaches ecto-CD38 via its export by connexin (Cx43) hemichannels, a component of gap junctions. NAD 37-43 CD38 antigen Mus musculus 60-64 21937766-4 2011 We found that rhythmicity of NAD(+) was altered in the CD38-deficient mice. NAD 29-35 CD38 antigen Mus musculus 55-59 21937766-8 2011 Metabolomic analysis identified alterations in the circadian levels of several amino acids, specifically tryptophan levels were reduced in the CD38-null mice at a circadian time paralleling with elevated NAD(+) levels. NAD 204-210 CD38 antigen Mus musculus 143-147 20975043-4 2010 Moreover, lower T reg cell numbers are found in mice deficient for the NAD-hydrolase CD38 than in wild-type, P2X7-deficient, or ART2-deficient mice, indicating a role for extracellular NAD(+) in T reg cell homeostasis. NAD 185-191 CD38 antigen Mus musculus 85-89 20551293-3 2010 We first showed that morphine"s antinociceptive potency was increased by the intracerebroventricular injection of CD38 substrate beta-NAD(+) in mice. NAD 129-140 CD38 antigen Mus musculus 114-118 20638362-1 2010 CD38 is a multifunctional enzyme that has both ADP-ribosyl cyclase and cADPR hydrolase activities, being capable of cleaving NAD(+) to cyclic ADP ribose (cADPR) and hydrolyzing cADPR to ADPR. NAD 125-131 CD38 antigen Mus musculus 0-4 20638362-2 2010 It has been reported that there is markedly a reduction of cADPR and elevation of NAD in many tissues from CD38 knockout (CD38(-/-)) mice. NAD 82-85 CD38 antigen Mus musculus 107-111 20638362-2 2010 It has been reported that there is markedly a reduction of cADPR and elevation of NAD in many tissues from CD38 knockout (CD38(-/-)) mice. NAD 82-85 CD38 antigen Mus musculus 122-126 20638362-4 2010 We hypothesize that CD38 knockout may have a protective effect in oxidative stresses through elevating NAD and decreasing cADPR. NAD 103-106 CD38 antigen Mus musculus 20-24 19454650-6 2009 Additionally, extracellular ADPR production by the ectoenzyme CD38 from its substrates NAD+ (nicotinamide adenine dinucleotide) or cADPR causes IP3-dependent Ca2+ release via P2Y and adenosine receptors. NAD 87-91 CD38 antigen Mus musculus 62-66 19796917-3 2010 Diminished activity of the CD38 ectoenzyme that normally represents a counter-regulatory competitor for the NAD substrate represents one mechanism enhancing ART2.2 activity. NAD 108-111 CD38 antigen Mus musculus 27-31 19454650-6 2009 Additionally, extracellular ADPR production by the ectoenzyme CD38 from its substrates NAD+ (nicotinamide adenine dinucleotide) or cADPR causes IP3-dependent Ca2+ release via P2Y and adenosine receptors. NAD 93-126 CD38 antigen Mus musculus 62-66 18752667-5 2008 Given that increased levels of nicotinamide adenine dinucleotide (NAD) via deletion of CD38 have been shown to prevent high fat diet induced obesity in mice in a SIRT-1 dependent fashion we explored the possibility of directly applying NAD to zebrafish. NAD 31-64 CD38 antigen Mus musculus 87-91 18931329-1 2009 The multifunctional surface protein CD38 acts as a receptor with ecto-enzymatic activity, hydrolyzing NAD to generate several products known to exhibit Ca2+-mobilizing properties. NAD 102-105 CD38 antigen Mus musculus 36-40 18752667-5 2008 Given that increased levels of nicotinamide adenine dinucleotide (NAD) via deletion of CD38 have been shown to prevent high fat diet induced obesity in mice in a SIRT-1 dependent fashion we explored the possibility of directly applying NAD to zebrafish. NAD 66-69 CD38 antigen Mus musculus 87-91 17380200-8 2006 Finally, crosstalk between CD38 and other NAD(+) utilizing enzymes such as ART2, SIRT1, and PARP-1 impacts NAD(+) homeostasis, inflammation, and immunity. NAD 42-48 CD38 antigen Mus musculus 27-31 18166151-3 2008 Here we show that extracellular NAD enhances Fcgamma receptor (FcgammaR)-mediated phagocytosis in J774A.1 macrophages via the conversion into cyclic ADP-ribose (cADPR), a potent calcium mobilizer, by CD38, an ADP-ribosyl cyclase. NAD 32-35 CD38 antigen Mus musculus 200-204 18166151-4 2008 Extracellular NAD increased the phagocytosis of IgG-coated sheep red blood cells (IgG-SRBC) in J774A.1 macrophages, which was completely abolished by pretreatment of 8-bromo-cADPR, an antagonist of cADPR, or CD38 knockdown. NAD 14-17 CD38 antigen Mus musculus 208-212 18166151-5 2008 Extracellular NAD increased basal intracellular Ca(2+) concentration, which also was abolished by pretreatment of 8-bromo-cADPR or CD38 knockdown. NAD 14-17 CD38 antigen Mus musculus 131-135 18025229-1 2007 The ectoenzyme CD38 catalyzes the production of cyclic ADP-ribose (cADPR) and ADP-ribose (ADPR) from its substrate, NAD(+). NAD 116-122 CD38 antigen Mus musculus 15-19 17579037-6 2007 Intravenous injection of NAD(+) used to exacerbate NICD in vivo results in fast and dramatic ART2- and P2X7-dependent depletion of CD4+ and CD8+ T lymphocytes, which can affect up to 80% of peripheral T cells in CD38(-/-) mice. NAD 25-31 CD38 antigen Mus musculus 212-216 17579037-8 2007 Consistently, treatment with NAD(+) abolishes primary Ab response to a T-dependent Ag in NICD-susceptible CD38(-/-) mice but has no effect on the secondary response when given several days after priming. NAD 29-35 CD38 antigen Mus musculus 106-110 17380200-8 2006 Finally, crosstalk between CD38 and other NAD(+) utilizing enzymes such as ART2, SIRT1, and PARP-1 impacts NAD(+) homeostasis, inflammation, and immunity. NAD 107-113 CD38 antigen Mus musculus 27-31 16935261-0 2006 Regulation of SIRT 1 mediated NAD dependent deacetylation: a novel role for the multifunctional enzyme CD38. NAD 30-33 CD38 antigen Mus musculus 103-107 16956582-7 2006 As CD38 is the major NAD+ -degrading enzyme present in the bone marrow, these results suggest that CD38-mediated inhibition of osteoclastogenesis is related to its NADase activity, not its ADPribosyl cyclase activity. NAD 21-25 CD38 antigen Mus musculus 3-7 16956582-7 2006 As CD38 is the major NAD+ -degrading enzyme present in the bone marrow, these results suggest that CD38-mediated inhibition of osteoclastogenesis is related to its NADase activity, not its ADPribosyl cyclase activity. NAD 21-25 CD38 antigen Mus musculus 99-103 16935261-4 2006 However, the major enzymatic activity of CD38 is the hydrolysis of NAD. NAD 67-70 CD38 antigen Mus musculus 41-45 16935261-7 2006 We propose that by modulating availability of NAD to the SIRT1 enzyme, CD38 may regulate SIRT1 enzymatic activity. NAD 46-49 CD38 antigen Mus musculus 71-75 16935261-8 2006 We observed that in CD38 knockout mice, tissue levels of NAD are significantly increased. NAD 57-60 CD38 antigen Mus musculus 20-24 16935261-13 2006 Our data support the novel concept that nuclear CD38 is a major regulator of cellular/nuclear NAD level, and SIRT1 activity. NAD 94-97 CD38 antigen Mus musculus 48-52 16730329-0 2006 Regulation of intracellular levels of NAD: a novel role for CD38. NAD 38-41 CD38 antigen Mus musculus 60-64 16750163-0 2006 Decreased cADPR and increased NAD+ in the Cd38-/- mouse. NAD 30-34 CD38 antigen Mus musculus 42-46 16750163-1 2006 CD38 is a type II glycoprotein that catalyzes the formation of cyclic ADP-ribose (cADPR), an intracellular calcium signalling molecule, from nicotinamide adenine dinucleotide (NAD(+)). NAD 141-174 CD38 antigen Mus musculus 0-4 16750163-1 2006 CD38 is a type II glycoprotein that catalyzes the formation of cyclic ADP-ribose (cADPR), an intracellular calcium signalling molecule, from nicotinamide adenine dinucleotide (NAD(+)). NAD 176-182 CD38 antigen Mus musculus 0-4 16750163-4 2006 We also report significant increases in brain, lung, and kidney NAD(+) in the Cd38(-/-) mouse, and provide the first experimental demonstration of the proximate relationship between CD38 and NAD(+). NAD 64-70 CD38 antigen Mus musculus 78-82 16750163-4 2006 We also report significant increases in brain, lung, and kidney NAD(+) in the Cd38(-/-) mouse, and provide the first experimental demonstration of the proximate relationship between CD38 and NAD(+). NAD 191-197 CD38 antigen Mus musculus 182-186 16730329-8 2006 However, its major enzymatic activity is the hydrolysis of NAD, in fact, CD38 will generate one molecule of cADPR for every 100 molecules of NAD hydrolyzed. NAD 59-62 CD38 antigen Mus musculus 73-77 16730329-8 2006 However, its major enzymatic activity is the hydrolysis of NAD, in fact, CD38 will generate one molecule of cADPR for every 100 molecules of NAD hydrolyzed. NAD 141-144 CD38 antigen Mus musculus 73-77 16730329-9 2006 To date, the role of CD38 as a modulator of levels of NAD has not been explored. NAD 54-57 CD38 antigen Mus musculus 21-25 16730329-12 2006 In accordance with our hypothesis, we found that tissue levels of NAD in CD38 deficient mice are 10- to 20-fold higher than in wild-type animals. NAD 66-69 CD38 antigen Mus musculus 73-77 16730329-14 2006 These data support the novel concept that CD38 is a major regulator of cellular NAD levels. NAD 80-83 CD38 antigen Mus musculus 42-46 12403647-2 2003 In addition to its major NAD+-glycohydrolase activity, CD38 is also able to synthesize cyclic ADP-ribose, an endogenous calcium-regulating molecule, from NAD+. NAD 25-29 CD38 antigen Mus musculus 55-59 16585549-14 2006 Both ART2-deficient and CD38/ART2 combined deficient T cells were resistant to NAD-induced killing in vitro, whereas CD38-deficient but ART2-intact T cells showed increased sensitivity, particularly the CD4+ CD25+ subset. NAD 79-82 CD38 antigen Mus musculus 24-28 12909645-4 2003 To address this question, NAD+ metabolizing activities were accurately examined in developing and adult Cd38-/- mouse brain protein extracts and cells. NAD 26-30 CD38 antigen Mus musculus 104-108 12631576-2 2003 CD38 catalyzes the cyclization of its substrate, NAD+, to the Ca2+-releasing second messenger, cyclic ADP-ribose (cADPr). NAD 49-53 CD38 antigen Mus musculus 0-4 12631576-13 2003 We speculate that CD38 functions as a cellular NAD+ "sensor," particularly during periods of active motility and secretion. NAD 47-51 CD38 antigen Mus musculus 18-22 16585549-1 2006 Ubiquitously expressed CD38 and T cell-expressed ADP-ribosyltransferase 2 (ART2) are ectoenzymes competing for NAD substrate. NAD 111-114 CD38 antigen Mus musculus 23-27 16442077-12 2006 Physiologically, therefore, modulation of the expression of the NAD(+)-sensing enzyme, CD38, by Ca(2+), cAMP, and cytokines, such as TNF-alpha may contribute to coupling the intense metabolic activity of osteoclasts and osteoblasts to their respective bone-resorbing and bone-forming functions. NAD 64-70 CD38 antigen Mus musculus 87-91 15781114-2 2005 As an enzyme, CD38 catalyzes the conversion of NAD(+) and NADP to several metabolites including cADPR and NAADP, which mediate Ca(2+) release from separate intracellular stores, and ADPR, which activates the TRPM2 plasma membrane Ca(2+) channel. NAD 47-53 CD38 antigen Mus musculus 14-18 14709821-1 2003 CD38 is an ectoenzyme with ADP-ribosyl cyclase and hydrolase activities, which synthesizes cyclic ADP-ribose from NAD and hydrolyzes cyclic ADP-ribose to ADP-ribose. NAD 114-117 CD38 antigen Mus musculus 0-4 11602597-0 2001 A self-restricted CD38-connexin 43 cross-talk affects NAD+ and cyclic ADP-ribose metabolism and regulates intracellular calcium in 3T3 fibroblasts. NAD 54-58 CD38 antigen Mus musculus 18-22 12368285-1 2002 In mammals cyclic ADP-ribose (cADPR), a universal calcium mobilizer from intracellular stores, is generated from NAD(+) at the outer cell surface by the multifunctional ectoenzyme CD38 and by related ADP-ribosyl cyclases. NAD 113-119 CD38 antigen Mus musculus 180-184 11874980-0 2002 A novel mechanism for coupling cellular intermediary metabolism to cytosolic Ca2+ signaling via CD38/ADP-ribosyl cyclase, a putative intracellular NAD+ sensor. NAD 147-151 CD38 antigen Mus musculus 96-100 11874980-1 2002 CD38 is an ectocyclase that converts NAD+ to the Ca2+-releasing second messenger cyclic ADP-ribose (cADPr). NAD 37-41 CD38 antigen Mus musculus 0-4 11874980-2 2002 Here we report that in addition to CD38 ecto-catalysis, intracellularly expressed CD38 may catalyze NAD+-->cADPr conversion to cause cytosolic Ca2+ release. NAD 100-106 CD38 antigen Mus musculus 82-86 11874980-8 2002 The Delta(-49)-CD38-EGFP mutant with a deleted amino-terminal tail and transmembrane domain appeared mainly in the mitochondria with an expected loss of its membrane localization, but the NAD+-induced cytosolic Ca2+ signal was preserved. NAD 188-192 CD38 antigen Mus musculus 15-19 11874980-11 2002 We conclude that intracellularly expressed CD38 might link cellular NAD+ production to cytosolic Ca2+ signaling. NAD 68-72 CD38 antigen Mus musculus 43-47 11602597-7 2001 This mechanism may avoid: (i) leakage of NAD(+) from cells; (ii) depletion of intracellular NAD(+) by CD38; (iii) overproduction of intracellular cADPR resulting in potentially cytotoxic [Ca(2+)](i). NAD 41-47 CD38 antigen Mus musculus 102-106 11602597-7 2001 This mechanism may avoid: (i) leakage of NAD(+) from cells; (ii) depletion of intracellular NAD(+) by CD38; (iii) overproduction of intracellular cADPR resulting in potentially cytotoxic [Ca(2+)](i). NAD 92-98 CD38 antigen Mus musculus 102-106 11602597-1 2001 Connexin 43 (Cx43) hexameric hemichannels, recently demonstrated to mediate NAD(+) transport, functionally interact in the plasma membrane of several cells with the ectoenzyme CD38 that converts NAD(+) to the universal calcium mobilizer cyclic ADP-ribose (cADPR). NAD 76-82 CD38 antigen Mus musculus 176-180 11602597-1 2001 Connexin 43 (Cx43) hexameric hemichannels, recently demonstrated to mediate NAD(+) transport, functionally interact in the plasma membrane of several cells with the ectoenzyme CD38 that converts NAD(+) to the universal calcium mobilizer cyclic ADP-ribose (cADPR). NAD 195-201 CD38 antigen Mus musculus 176-180 11602597-2 2001 Here we demonstrate that functional uncoupling between CD38 and Cx43 in CD38-transfected 3T3 murine fibroblasts is paralleled by decreased [Ca(2+)](i) levels as a result of reduced intracellular conversion of NAD(+) to cADPR. NAD 209-215 CD38 antigen Mus musculus 55-59 11602597-2 2001 Here we demonstrate that functional uncoupling between CD38 and Cx43 in CD38-transfected 3T3 murine fibroblasts is paralleled by decreased [Ca(2+)](i) levels as a result of reduced intracellular conversion of NAD(+) to cADPR. NAD 209-215 CD38 antigen Mus musculus 72-76 11602597-3 2001 A sharp inverse correlation emerged between [Ca(2+)](i) levels and NAD(+) transport (measured as influx into cells and as efflux therefrom), both in the CD38(+) cells (high [Ca(2+)](i), low transport) and in the CD38(-) fibroblasts (low [Ca(2+)](i), high transport). NAD 67-73 CD38 antigen Mus musculus 153-157 11602597-3 2001 A sharp inverse correlation emerged between [Ca(2+)](i) levels and NAD(+) transport (measured as influx into cells and as efflux therefrom), both in the CD38(+) cells (high [Ca(2+)](i), low transport) and in the CD38(-) fibroblasts (low [Ca(2+)](i), high transport). NAD 67-73 CD38 antigen Mus musculus 212-216 11274199-1 2001 CD38 is a bifunctional ectoenzyme synthesizing from NAD(+) (ADP-ribosyl cyclase) and degrading (hydrolase) cyclic ADP-ribose (cADPR), a powerful universal calcium mobilizer from intracellular stores. NAD 52-58 CD38 antigen Mus musculus 0-4 11508269-4 2001 METHODS: ART2.2 and CD38, another NAD-utilizing enzyme, were measured by flow cytometry. NAD 34-37 CD38 antigen Mus musculus 20-24 10891341-7 2000 We finally confirmed the ADP-ribosyl cyclase activity of the expressed CD38 by measuring its ability to catalyze the cyclization of the nicotinamide adenine dinucleotide (NAD(+)) surrogate, NGD(+), to its fluorescent nonhydrolyzable derivative, cGDPr. NAD 136-169 CD38 antigen Mus musculus 71-75 11401531-4 2001 NAD-dependent inactivation and ADP-ribosylation of CD38, intracellular concentrations of cADPR and Ca(2+), and insulin secretion were measured following incubation of mouse pancreatic islet cells with NAD. NAD 0-3 CD38 antigen Mus musculus 51-55 10891341-7 2000 We finally confirmed the ADP-ribosyl cyclase activity of the expressed CD38 by measuring its ability to catalyze the cyclization of the nicotinamide adenine dinucleotide (NAD(+)) surrogate, NGD(+), to its fluorescent nonhydrolyzable derivative, cGDPr. NAD 171-178 CD38 antigen Mus musculus 71-75 9525901-4 1998 Here we demonstrate that ectocellular expression of human CD38 in CD38(-) HeLa and 3T3 cells results in intracellular CD38 substrate (NAD+ + NADH) consumption and product (cADPR) accumulation. NAD 134-138 CD38 antigen Mus musculus 66-70 9694721-2 1998 The extracellular domain of CD38 can mediate the catalysis of NAD+ to cyclic adenosine diphosphoribose (cADPR), a Ca2+-mobilizing second messenger, adenosine diphosphoribose (ADPR), and nicotinamide. NAD 62-66 CD38 antigen Mus musculus 28-32 9525901-4 1998 Here we demonstrate that ectocellular expression of human CD38 in CD38(-) HeLa and 3T3 cells results in intracellular CD38 substrate (NAD+ + NADH) consumption and product (cADPR) accumulation. NAD 141-145 CD38 antigen Mus musculus 66-70 8881035-2 1996 The deduced amino acid sequence of Bp3 cDNA shares significant similarity to human and mouse CD38 and molluscan ADP-ribosyl cyclase, enzymes that generate the calcium mobilizing agent cyclic ADP-ribose from NAD. NAD 207-210 CD38 antigen Mus musculus 93-97 9378973-0 1997 Human CD38, a leukocyte receptor and ectoenzyme, is a member of a novel eukaryotic gene family of nicotinamide adenine dinucleotide+-converting enzymes: extensive structural homology with the genes for murine bone marrow stromal cell antigen 1 and aplysian ADP-ribosyl cyclase. NAD 98-131 CD38 antigen Mus musculus 6-10 9553766-3 1998 The structural homology between CD38 and the cyclase family members extends to functional homology, as the extracellular domain of CD38 can mediate the catalysis of beta-NAD+ into nicotinamide, ADP-ribose (ADPR) and, to a lesser extent, into cyclic ADPR-ribose (cADPR). NAD 165-174 CD38 antigen Mus musculus 32-36 9553766-3 1998 The structural homology between CD38 and the cyclase family members extends to functional homology, as the extracellular domain of CD38 can mediate the catalysis of beta-NAD+ into nicotinamide, ADP-ribose (ADPR) and, to a lesser extent, into cyclic ADPR-ribose (cADPR). NAD 165-174 CD38 antigen Mus musculus 131-135 7774637-1 1995 CD38 is a 42-kDa membrane associated enzyme which converts NAD into cyclic ADP-ribose (cADPR), a Ca(2+)-mobilizing second messenger, and ADP-ribose (ADPR). NAD 59-62 CD38 antigen Mus musculus 0-4 7576049-1 1995 CD38 is an ectoenzyme that utilizes NAD+ and is expressed by many cells of hematopoietic origin. NAD 36-40 CD38 antigen Mus musculus 0-4 7774637-7 1995 CD38 immunoprecipitated from these B cell populations was normal in size and effectively hydrolyzed NAD, suggesting that the defect in CD38 signaling likely occurs downstream of CD38 itself. NAD 100-103 CD38 antigen Mus musculus 0-4 7774637-7 1995 CD38 immunoprecipitated from these B cell populations was normal in size and effectively hydrolyzed NAD, suggesting that the defect in CD38 signaling likely occurs downstream of CD38 itself. NAD 100-103 CD38 antigen Mus musculus 135-139 7774637-7 1995 CD38 immunoprecipitated from these B cell populations was normal in size and effectively hydrolyzed NAD, suggesting that the defect in CD38 signaling likely occurs downstream of CD38 itself. NAD 100-103 CD38 antigen Mus musculus 135-139 8235624-5 1993 Soluble CD38 catalyzed the formation and hydrolysis of cADPR when added to NAD+. NAD 75-79 CD38 antigen Mus musculus 8-12 34637964-1 2021 Cluster of differentiation (CD) 38, a major enzyme for nicotinamide adenine dinucleotide (NAD+) degradation, plays a key role in inflammation. NAD 55-88 CD38 antigen Mus musculus 0-34 34803499-0 2021 CD38 Deficiency Protects Mice from High Fat Diet-Induced Nonalcoholic Fatty Liver Disease through Activating NAD+/Sirtuins Signaling Pathways-Mediated Inhibition of Lipid Accumulation and Oxidative Stress in Hepatocytes. NAD 109-113 CD38 antigen Mus musculus 0-4 34493542-2 2021 CD38 shows increased expression in the cuprizone and experimental autoimmune encephalomyelitis models of demyelination; in addition, CD38 is the main nicotinamide adenine dinucleotide (NAD+)-depleting enzyme in the CNS. NAD 150-183 CD38 antigen Mus musculus 0-4 34493542-2 2021 CD38 shows increased expression in the cuprizone and experimental autoimmune encephalomyelitis models of demyelination; in addition, CD38 is the main nicotinamide adenine dinucleotide (NAD+)-depleting enzyme in the CNS. NAD 150-183 CD38 antigen Mus musculus 133-137 34493542-2 2021 CD38 shows increased expression in the cuprizone and experimental autoimmune encephalomyelitis models of demyelination; in addition, CD38 is the main nicotinamide adenine dinucleotide (NAD+)-depleting enzyme in the CNS. NAD 185-189 CD38 antigen Mus musculus 0-4 34493542-2 2021 CD38 shows increased expression in the cuprizone and experimental autoimmune encephalomyelitis models of demyelination; in addition, CD38 is the main nicotinamide adenine dinucleotide (NAD+)-depleting enzyme in the CNS. NAD 185-189 CD38 antigen Mus musculus 133-137 34493542-5 2021 We demonstrate that CD38-catalytically inactive mice are substantially protected from high fat-induced NAD+ depletion, oligodendrocyte loss, oxidative damage, and astrogliosis. NAD 103-107 CD38 antigen Mus musculus 20-24 34493542-6 2021 A CD38 inhibitor, 78c, increased NAD+ and attenuated neuroinflammatory changes induced by saturated fat applied to astrocyte cultures. NAD 33-37 CD38 antigen Mus musculus 2-6 34493542-11 2021 Our findings suggest high fat diet impairs oligodendrocyte survival and differentiation through astrocyte-linked mechanisms mediated by the NAD+ase CD38 and highlight CD38 inhibitors as potential therapeutic candidates to improve myelin regeneration.SIGNIFICANCE STATEMENTMyelin disturbances and oligodendrocyte loss can leave axons vulnerable leading to permanent neurologic deficits. NAD 140-144 CD38 antigen Mus musculus 148-152 34493542-13 2021 We demonstrate that restoring nicotinamide adenine dinucleotide (NAD+) levels via genetic inactivation of CD38 can overcome these effects. NAD 30-63 CD38 antigen Mus musculus 106-110 34493542-13 2021 We demonstrate that restoring nicotinamide adenine dinucleotide (NAD+) levels via genetic inactivation of CD38 can overcome these effects. NAD 65-69 CD38 antigen Mus musculus 106-110 34539634-1 2021 CD38 is the major NAD+-hydrolyzing ecto-enzyme in most mammals. NAD 18-22 CD38 antigen Mus musculus 0-4 35441488-1 2022 OBJECTIVE: To observe expression of CD38, a key modulator of nicotinamide dinucleotide (NAD+) metabolism in mice with knee osteoarthritis, and protective effect of CD38 inhibition during the osteoarthritis (OA) development. NAD 88-92 CD38 antigen Mus musculus 36-40 35263032-2 2022 The NADase CD38 plays a key role in age-related NAD decline. NAD 48-51 CD38 antigen Mus musculus 11-15 35138178-11 2022 In diseases in which CD38 appears to play a role, CD38-dependent NAD decline is often a common denominator of pathophysiology. NAD 65-68 CD38 antigen Mus musculus 21-25 35138178-11 2022 In diseases in which CD38 appears to play a role, CD38-dependent NAD decline is often a common denominator of pathophysiology. NAD 65-68 CD38 antigen Mus musculus 50-54 34637964-1 2021 Cluster of differentiation (CD) 38, a major enzyme for nicotinamide adenine dinucleotide (NAD+) degradation, plays a key role in inflammation. NAD 90-94 CD38 antigen Mus musculus 0-34 34637964-7 2021 However, CD38 inhibition by 78c elevated intracellular NAD+ levels and suppressed IL-1beta release in MSU crystals-treated THP-1 macrophages and BMDMs. NAD 55-59 CD38 antigen Mus musculus 9-13 34637964-9 2021 In conclusion, the present study revealed that MSU crystals could activate CD38 with the ensuing intracellular NAD+ decline to promote inflammatory responses in THP-1 macrophages and BMDMs, while CD38 inhibition could suppress MSU crystals-triggered inflammatory responses, indicating that CD38 is a potential therapeutic target for gout. NAD 111-115 CD38 antigen Mus musculus 75-79 34637964-9 2021 In conclusion, the present study revealed that MSU crystals could activate CD38 with the ensuing intracellular NAD+ decline to promote inflammatory responses in THP-1 macrophages and BMDMs, while CD38 inhibition could suppress MSU crystals-triggered inflammatory responses, indicating that CD38 is a potential therapeutic target for gout. NAD 111-115 CD38 antigen Mus musculus 290-294 34803499-10 2021 More importantly, Ex527 (Sirt1 inhibitor) and 3-TYP (Sirt3 inhibitor) significantly enhanced OA-induced lipid accumulation and oxidative stress in CD38-/- primary hepatocytes, suggesting that the anti-lipid accumulation of CD38 deficiency might be dependent on NAD/Sirtuins-mediated enhancement of FAA beta-oxidation and suppression of oxidative stress in hepatocytes. NAD 261-264 CD38 antigen Mus musculus 223-227 34803499-11 2021 In conclusion, we demonstrated that CD38 deficiency protected mice from HFD-induced NAFLD by reducing lipid accumulation and suppressing oxidative stress via activating NAD/Sirtuins signaling pathways. NAD 169-172 CD38 antigen Mus musculus 36-40 34112762-7 2021 In conclusion, our findings demonstrated that CD38 and its associated intracellular NAD decline are critical for Ang II-induced VSMC senescence and vascular remodeling. NAD 84-87 CD38 antigen Mus musculus 46-50 35087020-9 2022 At the functional level, the reduction of senescence-associated inflammation ensured sustained NAD+ levels in the plasma of AAV-LAV-BPIFB4 old mice by preventing the NADase CD38 increase in F4/80+ tissue-resident macrophages and Ly6Chigh pro-inflammatory monocytes of the spleen and bone marrow. NAD 95-99 CD38 antigen Mus musculus 173-177